Canaccord Genuity Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $22
Portfolio Pulse from jenniferd'souza@benzinga.com
Canaccord Genuity analyst William Plovanic maintains a 'Buy' rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and raises the price target from $21 to $22.
July 25, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Y-mAbs Therapeutics and raises the price target from $21 to $22. This could potentially lead to an increase in the stock price.
The 'Buy' rating maintained by Canaccord Genuity indicates their positive outlook on the company. The increase in price target from $21 to $22 suggests that they expect the stock price to rise in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100